AllianceBernstein
BMRN icon

AllianceBernstein’s BioMarin Pharmaceuticals BMRN Stock Holding History

AllianceBernstein’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-40,000
Closed -$3.77M – 3139
2018
Q2 		$3.77M Buy
+40,000
New +$3.5M ﹤0.01% 1444

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AllianceBernstein's BMRN Position: Q1 2026 in Review

AllianceBernstein reduced its BioMarin Pharmaceuticals (BMRN) stake by 6.3% in Q1 2026, selling an estimated $977K and leaving 248,157 shares worth $14.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1043.

AllianceBernstein first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $57.4M in Q3 2013. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • AllianceBernstein held 248,157 shares of BioMarin Pharmaceuticals worth $14.7M as of Q1 2026.
  • AllianceBernstein sold 16,759 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $977K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #1043 holding.
  • AllianceBernstein first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • AllianceBernstein's BioMarin Pharmaceuticals position peaked at $57.4M in Q3 2013.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.